ABCG2 and Patent ductus arteriosus: These DDI study results, in conjunction with plasma endogenous CP-I and PDA biomarker data, suggest that ritlecitinib does not inhibit BCRP, OATP1B1, and OAT3, despite an in vitro assessment surpassing the regulatory DDI risk cutoff of these transporters.